Illumina announced that it has acquired Fluent BioSciences, a developer of single-cell analysis technology.
In a statement, Illumina said the acquisition closed on Tuesday, June 9, and was funded with cash on hand. Additional financial details of the acquisition were not disclosed.
The Fluent team will join Illumina's. Illumina will remain an open next-generation sequencing platform; the company said that it is "committed to maintaining and supporting its existing single-cell partnerships."
Fluent's PIPseq V technology will be integrated into Illumina's product portfolio, with plans to build on Fluent's technology to develop comprehensive end-to-end solutions for single-cell analysis.
"The addition of Fluent BioSciences to Illumina will provide significant and new capabilities to our customers in a key growth area and advances our multiomics growth strategy," Steven Barnard, chief technology officer of Illumina, said.
"Single-cell research opens doors to new areas of discovery, and Fluent's innovative, accessible, and flexible single-cell method will accelerate our ability to deliver full multiomics solutions for our customers."
